Search hospitals > Illinois > Peoria
Illinois CancerCare-Peoria
Claim this profilePeoria, Illinois 61615
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Adenocarcinoma
688 reported clinical trials
9 medical researchers
Summary
Illinois CancerCare-Peoria is a medical facility located in Peoria, Illinois. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Adenocarcinoma and other specialties. Illinois CancerCare-Peoria is involved with conducting 688 clinical trials across 591 conditions. There are 9 research doctors associated with this hospital, such as Bryan A. Faller, James L. Wade, Leonard Klein, and Nguyet A Le-Lindqwister, MD.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderER positive
HER2 negative
Stage IV
Top PIs
Bryan A. FallerCrossroads Cancer Center1 year of reported clinical research
Expert in Cancer
Expert in Breast Cancer
220 reported clinical trials
287 drugs studied
James L. WadeDecatur Memorial Hospital3 years of reported clinical research
Studies Recurrence
Studies Breast Cancer
11 reported clinical trials
20 drugs studied
Leonard KleinIllinois Cancer Specialists3 years of reported clinical research
Studies Lymphoma
Studies B-Cell Lymphoma
10 reported clinical trials
26 drugs studied
Nguyet A Le-Lindqwister, MDIllinois Cancer Care5 years of reported clinical research
Studies Lymphoma
Studies Hodgkin's Lymphoma
4 reported clinical trials
10 drugs studied
Clinical Trials running at Illinois CancerCare-Peoria
Breast Cancer
Prostate Cancer
Lung Cancer
Cancer
Non-Small Cell Lung Cancer
Gastric Cancer
Esophageal Cancer
Bladder Cancer
Esophageal Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
Carvedilol
for Preventing Heart Problems in HER2 Positive Breast Cancer
This study is evaluating whether a drug used to treat high blood pressure and heart failure may help prevent heart damage in patients with breast cancer.
Recruiting2 awards Phase 323 criteria
Shorter Chemo-Immunotherapy Without Anthracyclines
for Breast Cancer
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
Chemotherapy + Hormone Therapy
for Breast Cancer
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).
Recruiting2 awards Phase 319 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Illinois CancerCare-Peoria?
Illinois CancerCare-Peoria is a medical facility located in Peoria, Illinois. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Adenocarcinoma and other specialties. Illinois CancerCare-Peoria is involved with conducting 688 clinical trials across 591 conditions. There are 9 research doctors associated with this hospital, such as Bryan A. Faller, James L. Wade, Leonard Klein, and Nguyet A Le-Lindqwister, MD.
Where is Illinois CancerCare-Peoria located?
**Illinois CancerCare - Peoria Hospital**
- **Address:** 8940 N Wood Sage Rd, Peoria, IL 61615
- **Hours:**
- Monday to Thursday: 7:30 AM - 5:00 PM
- Friday: 8:00 AM - 5:00 PM
Who should I call to ask about financial aid or insurance network?
**Illinois CancerCare-Peoria Financial Assistance:**
- For financial assistance, contact OSF HealthCare Patient Financial Services at (800) 421-5700 or visit 1420 W. Pioneer Parkway, Peoria, IL 61615.
- Assistance is available for those who qualify, including the uninsured and underinsured. Proof of income and state residency is required.
- Pre-approval for financial assistance is available and typically processed within two weeks, valid for 12 months.
**Insurance Inquiries:**
- For insurance questions, contact Illinois CancerCare-Peoria at (309) 243-3000 or (866) 662-6564, or visit 8940 N Wood Sage Rd, Peoria, IL 61615.
- They address inquiries related to treatment, research, and education in the fight against cancer and blood disorders.
What insurance does Illinois CancerCare-Peoria accept?
Illinois CancerCare-Peoria accepts a range of insurance plans, both commercial and government. Patients with HMO or PPO plans should verify if specific physicians are covered. It's also recommended to check if pre-certification is required with your insurance plan.
What awards or recognition has Illinois CancerCare-Peoria received?
Illinois CancerCare-Peoria, located in Peoria, Illinois, is renowned for its exceptional contribution to clinical research, being named one of the nation's top enrollers by the Alliance for Clinical Trials in Oncology in 2015. The hospital has also earned recognition from the Quality Oncology Practice Initiative (QOPI®) Certification Program, affirming its adherence to the highest standards of quality cancer care. Demonstrating its commitment to advancing cancer treatment, Illinois CancerCare-Peoria has successfully enrolled 201 patients into 30 different NCI-funded clinical trials across more than 15 cancer types.